Dr. Jeffrey R. Jay, M.D.
Latest statistics and disclosures from Great Point Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APGE, VOR, ZURA, AMLX, IBRX, and represent 31.05% of Great Point Partners's stock portfolio.
- Added to shares of these 10 stocks: IBRX (+$23M), SLGL (+$22M), ALMS (+$19M), DRUG (+$16M), ANNX (+$14M), ZBIO (+$10M), MLTX (+$9.3M), VERA (+$8.0M), NKTR (+$7.6M), LBRX (+$7.4M).
- Started 21 new stock positions in ZBIO, ALMS, IRD, DRUG, SLGL, SCYX, MLTX, AVXL, TENX, ALKS. CMPX, PALI, LBRX, ANNX, RLMD, VERA, PMN, IMMX, GALT, HUMA, IBRX.
- Reduced shares in these 10 stocks: IRON (-$20M), RAPT (-$20M), SLNO (-$19M), DNTH (-$14M), FULC (-$9.0M), UPB (-$8.1M), RARE (-$6.9M), CNTX (-$6.4M), IMVT (-$5.1M), CGEM.
- Sold out of its positions in DNTH, IRON, FULC, RAPT, SANA, SLNO, RARE, UPB.
- Great Point Partners was a net buyer of stock by $87M.
- Great Point Partners has $435M in assets under management (AUM), dropping by 41.08%.
- Central Index Key (CIK): 0001281446
Tip: Access up to 7 years of quarterly data
Positions held by Dr. Jeffrey R. Jay, M.D. consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Great Point Partners
Great Point Partners holds 42 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 7.2 | $32M | 374k | 84.17 |
|
|
| Vor Biopharma Com New (VOR) | 7.2 | $31M | +27% | 1.8M | 17.84 |
|
| Zura Bio Class A Ord Shs (ZURA) | 5.8 | $25M | +10% | 4.2M | 5.95 |
|
| Amylyx Pharmaceuticals (AMLX) | 5.6 | $24M | 1.8M | 13.90 |
|
|
| Immunitybio Put Option (IBRX) | 5.3 | $23M | NEW | 3.0M | 7.67 |
|
| Nektar Therapeutics Com New (NKTR) | 5.2 | $23M | +50% | 317k | 71.95 |
|
| Sol-gel Technologies Shs New (SLGL) | 5.0 | $22M | NEW | 274k | 79.22 |
|
| Alumis (ALMS) | 4.3 | $19M | NEW | 856k | 22.03 |
|
| Bright Minds Biosciences Com New (DRUG) | 3.7 | $16M | NEW | 220k | 72.97 |
|
| Annexon (ANNX) | 3.2 | $14M | NEW | 2.5M | 5.54 |
|
| Kalvista Pharmaceuticals (KALV) | 3.1 | $14M | 675k | 20.13 |
|
|
| Immunovant (IMVT) | 3.1 | $14M | -27% | 546k | 24.84 |
|
| Jade Biosciences Com New (JBIO) | 3.1 | $14M | +19% | 965k | 14.05 |
|
| Contineum Therapeutics Cl A (CTNM) | 2.4 | $11M | 800k | 13.06 |
|
|
| Zenas Biopharma (ZBIO) | 2.4 | $10M | NEW | 524k | 19.55 |
|
| Neurogene (NGNE) | 2.3 | $10M | +42% | 500k | 20.16 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.1 | $9.3M | NEW | 500k | 18.64 |
|
| Eliem Therapeutics (CLYM) | 2.1 | $9.1M | +36% | 1.3M | 6.85 |
|
| Oruka Therapeutics (ORKA) | 2.1 | $9.0M | 183k | 49.05 |
|
|
| Eupraxia Pharmaceuticals (EPRX) | 2.0 | $8.7M | 1.2M | 7.24 |
|
|
| Vera Therapeutics Cl A (VERA) | 1.8 | $8.0M | NEW | 199k | 40.23 |
|
| Evommune Com Shs (EVMN) | 1.7 | $7.5M | 325k | 22.99 |
|
|
| Lb Pharmaceuticals Com Shs (LBRX) | 1.7 | $7.4M | NEW | 300k | 24.66 |
|
| Compass Therapeutics (CMPX) | 1.6 | $7.1M | NEW | 1.4M | 5.29 |
|
| Scynexis Com New (SCYX) | 1.6 | $6.9M | NEW | 7.6M | 0.92 |
|
| Palisade Bio (PALI) | 1.4 | $6.0M | NEW | 3.4M | 1.75 |
|
| Context Therapeutics (CNTX) | 1.3 | $5.9M | -52% | 2.2M | 2.62 |
|
| Relmada Therapeutics (RLMD) | 1.3 | $5.9M | NEW | 842k | 6.96 |
|
| Silence Therapeutics Ads (SLN) | 1.2 | $5.4M | +26% | 1.0M | 5.27 |
|
| Unicycive Therapeutics Com New (UNCY) | 1.2 | $5.2M | 797k | 6.58 |
|
|
| Tenax Therapeutics Com New (TENX) | 1.2 | $5.2M | NEW | 327k | 15.99 |
|
| Promis Neurosciences Com Shs (PMN) | 1.1 | $4.7M | NEW | 371k | 12.70 |
|
| Cullinan Oncology (CGEM) | 1.0 | $4.3M | -52% | 300k | 14.21 |
|
| Immix Biopharma (IMMX) | 0.7 | $3.2M | NEW | 350k | 9.11 |
|
| Rezolute Com New (RZLT) | 0.7 | $2.9M | 952k | 3.05 |
|
|
| Pharvaris N V (PHVS) | 0.5 | $2.3M | 83k | 28.25 |
|
|
| Humacyte (HUMA) | 0.5 | $2.3M | NEW | 3.8M | 0.61 |
|
| Galectin Therapeutics Com New Call Option (GALT) | 0.5 | $2.2M | NEW | 800k | 2.79 |
|
| Avalo Therapeutics Com New (AVTX) | 0.4 | $1.9M | 125k | 14.93 |
|
|
| Alkermes SHS (ALKS) | 0.4 | $1.8M | NEW | 50k | 35.36 |
|
| Anavex Life Sciences Corp Com New Call Option (AVXL) | 0.4 | $1.6M | NEW | 521k | 3.07 |
|
| Ocuphire Pharma (IRD) | 0.3 | $1.5M | NEW | 324k | 4.55 |
|
Past Filings by Great Point Partners
SEC 13F filings are viewable for Great Point Partners going back to 2013
- Great Point Partners 2026 Q1 filed May 15, 2026
- Great Point Partners 2025 Q4 filed Feb. 17, 2026
- Great Point Partners 2025 Q3 filed Nov. 14, 2025
- Great Point Partners 2025 Q2 filed Aug. 14, 2025
- Great Point Partners 2025 Q1 filed May 15, 2025
- Great Point Partners 2024 Q4 filed Feb. 14, 2025
- Great Point Partners 2024 Q3 filed Nov. 13, 2024
- Great Point Partners 2024 Q2 filed Aug. 14, 2024
- Great Point Partners 2024 Q1 filed May 15, 2024
- Great Point Partners 2023 Q4 filed Feb. 14, 2024
- Great Point Partners 2023 Q3 filed Nov. 14, 2023
- Great Point Partners 2023 Q2 filed Aug. 14, 2023
- Great Point Partners 2023 Q1 filed May 15, 2023
- Great Point Partners 2022 Q4 filed Feb. 14, 2023
- Great Point Partners 2022 Q3 filed Nov. 14, 2022
- Great Point Partners 2022 Q2 filed Aug. 15, 2022